

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092106 A1

(51) International Patent Classification⁷: **A61K 31/7048**,
31/7042, 31/365, 47/30, A61P 31/00

(21) International Application Number: **PCT/NZ02/00091**

(22) International Filing Date: **9 May 2002 (09.05.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
511657 **11 May 2001 (11.05.2001)** **NZ**

(71) Applicant (for all designated States except US): **PA-
CIFIC PHARMACEUTICALS LIMITED [NZ/NZ];**
76, Leonard Road, Mt Wellington, Auckland (NZ).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FERGUSON,**
Phillip, John [NZ/NZ]; 14 Kowhai Avenue, Kaiaua,
Auckland (NZ). **HILLIER, Charles [NZ/NZ];** 22 Gwe-
nend Place, Howick, Auckland (NZ).

(74) Agents: **PIPER, James, William et al.;** Pipers, Unicorn
House, 300A Richmond Road, Grey Lynn, Auckland 1002
(NZ).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **TASTE MASKING PHARMACEUTICAL COMPOSITION**

(57) Abstract: The invention describes a composition suitable for oral administration comprising an antibiotic macrolide and a polycarbophil. The antibiotic macrolide is preferably clarithromycin. The polycarbophil is reported to have surprising taste-masking properties in combination with the antibiotic and acts by inhibiting the undesirable release of the antibiotic component in the mouth or stomach. Several methods of preparing granules of the antibiotic macrolide and polycarbophil are also described.

WO 02/092106 A1

TASTE MASKING PHARMACEUTICAL COMPOSITION

5

FIELD

This invention relates to pharmaceutical compositions suitable for oral administration comprising polycarbophil and a beneficial agent. In particular it relates to compositions which allow for the controlled release of the beneficial agent for the purpose of masking its taste.

BACKGROUND

Many prescription and non-prescription beneficial agents are known to have extremely unpleasant tastes. In particular the macrolide antibiotics, especially erythromycin and clarithromycin, have an extremely bitter taste making oral administration of these actives difficult. The administration of the macrolide antibiotics is often desirable in the treatment of children's ailments. As children cannot easily swallow tablets or capsules, it is preferable to provide them with medicaments in the form of suspensions or liquids. The extremely bitter taste of the above macrolide antibiotics makes this form of oral administration difficult to provide in that the children, and other patients, cannot tolerate the extremely unpleasant taste of the drug. There is therefore a need for palatable liquid dosage forms of beneficial agents and in particular the macrolide antibiotics.

25

OBJECT

It is an object of the present invention to provide an oral composition which can deliver a pharmaco-kinetically acceptable dosage of a beneficial agent, or to at least provide the public with a useful choice.

30

STATEMENT OF INVENTION

In a first aspect this invention provides a composition comprising a beneficial agent and polycarbophil.

- 5 In a second aspect this invention provides granules suitable for the preparation of liquid suspensions or dispersions for oral administration comprising a beneficial agent and polycarbophil.

- 10 Preferably the beneficial agent is a macrolide antibiotic, and in the most preferred compositions the beneficial agent is erythromycin, or a erythromycin derivative including clarithromycin.

- In a third aspect this invention provides a process for the production of granules comprising a beneficial agent and polycarbophil, suitable for the preparation of liquid
15 suspensions or dispersions for oral administration including the steps of:
blending the powders of polycarbophil and the beneficial agent in the required ratio;
adding a granulating fluid to the agitated blend to produce granules;
screening and drying the wet mass;
sizing the granules and collecting the preferred fraction.

20

Preferably the ratio of the beneficial agent and the polycarbophil is about 5:3

Preferably the granulating fluid is a solution of ethanol and water.


- 25 Preferably the granules are sized and regranulated with a binder solution.

Preferably the granules are coated in a polymeric coating.

- 30 The term macrolide antibiotic refers to a group of compounds having antibiotic activity and produced by *streptomyces* spp, characterised by having a macrocyclic ring, usually a 14-membered macrolactone ring and two O-linked sugar molecules.


This particular ring system includes the erythromycins A, B, C and D. Especially useful macrolide antibiotics are erythromycin, clarithromycin, and roxithromycin.

The Erythromycins have the formulae:



Name	Mol. Formula	R1	R2
erythromycin A	$C_{37}H_{67}NO_{13}$	OH	OCH_3
erythromycin B	$C_{37}H_{67}NO_{12}$	H	OCH_3
erythromycin C	$C_{36}H_{65}NO_{13}$	OH	OH

and Clarithromycin has the formula:



The compositions may also include the pharmaceutically acceptable salts and esters of the beneficial agent, or macrolide antibiotic.

Polycarbophil is a polymer of acrylic acid cross-linked with divinyl glycol. Polycarbophils are available through BF Goodrich as Noveon polycarbophils in both

the calcium salt and acid forms. Polycarbophil is a synthetic agent that is not absorbed into the body. In the past it has been used to promote regular bowel activity and for the treatment of chronic constipation, diverticulosis and irritable bowel syndrome. In this capacity its main function is to absorb water in the intestine to
5 create a bulkier and softer stool; it does not function as a laxative. For these purposes it is sold as an over the counter product under the trade names Fibercon, Equilactin and Mitrolan. Its use as a component in the preparation of taste-masking compositions for unpleasant or bitter-tasting beneficial agents such as the macrolide antibiotics has not previously been known.

10

While the invention is not to be limited to any theory, it is thought that the following process may be involved in the ability of the polycarbophil polymer to facilitate the taste masking of the active. In its dehydrated state polycarbophil is believed to be a tightly coiled molecule. On hydration however, it uncoils slightly and consequently
15 swells. Partial neutralisation by the basic groups of the beneficial agent causes further uncoiling, swelling and entrapment of the beneficial agent, both physically and possibly chemically. When the beneficial agent is a macrolide antibiotic such as erythromycin or clarithromycin, some ionic bonding between the amine group of the antibiotic and the carboxyl groups of the polycarbophil may be present. Literature
20 indicates that this chemical linkage exhibits optimum stability in the range pH 4 to 6 with dissolution of the antibiotic from the complex markedly increased at pH's outside this range. Because of this there is a possibility of an undesirable release of the active from the combination of antibiotic and polycarbophil in the acidic conditions of the stomach and neutral conditions of the mouth. In order to prevent
25 premature release of the drug and any resultant unpalatability of the composition it is desirable to provide the granules with an acid resistant coating. This protective coat allows rapid release of the drug in the higher pH environment of the duodenum and through the intestinal tract. Thus release of the antibiotic from the coated combination of antibiotic and polycarbophil is inhibited until after the composition
30 has passed through the mouth and stomach, therefore eliminating any of the tasting of the active by the patient.

By inhibiting the release of the active from the composition in the mouth and stomach the compositions of the invention provide palatable oral dosage forms of the antibiotics while maintaining acceptable pharmacokinetic properties. The polycarbophil is not absorbed into the body, and it is known from previous applications in the treatment of constipation to be safe for long term use.

Preferably the compositions of the invention are provided as granules to be used in the preparation of aqueous suspensions or dispersions. However, it is envisaged as being within the scope of the invention that the granules maybe employed in the preparation of other known dosage forms such as tablets, capsules and chewable preparations.

A preferred process for the production of the granules will be described by way of example only with reference to the flow diagram of Figure 1.

A selected ratio of the beneficial agent and polycarbophil powders are thoroughly blended. The preferred ratio of the powders is about 5:3 when the active ingredient is a macrolide antibiotic although any ratio which produces a therapeutically effective product is envisaged as being within the scope of this invention.

Any standard pharmaceutical blender may be used eg a planetary mixer has been found to be particularly suitable. Once the powders are blended a granulating solution of alcohol and water is added to the agitated blend over a period of about 1 hour to allow the granules to form. The head space temperature is maintained at below 60°C. The preferred granulating solution comprises ethanol in water in equal amounts by weight. It has been found that if only water is used as the granulating liquid the wet mass tends to granulate more rapidly and lump making granulation less satisfactory. The introduction of ethanol into the granulating solution slows down the process of gelation/granulation and gives improved granules. The resultant wet mass is screened and dried to LOD < 4%. The preferred drying temperature is 50°C. The dried mass is milled to a particle size of less than 800 µm. While the granules may be used at this stage it has been found that it is preferable to coat the resulting

granules with a polymeric coating and preferably prior to this step, to size and re-granulate with a binder solution. The sized granules are preferably regranulated with a 10% aqueous Povidone K90 binder solution. The resultant wet mass is screened and dried at 50°C to LOD < 4%. The dried material is then milled and sieved to
5 recover the fraction between 180 µm and 710 µm. The collection fraction is coated with a suitable aqueous enteric coating to enhance the taste masking function and the preferred material in this regard is Eudagrit L100-55 suspension. The granules are coated by fluidising in a fluid bed apparatus and spraying them with the coating suspension, although any of the well known methods for coating granules may be
10 employed. The coated granules are then re-sieved to recover the fraction between 180 µm and 710 µm. The finished granules may be mixed with sweeteners, flavouring agents, preservatives or any other ingredients which when dispersed in water provide a therapeutic composition suitable for oral administration. Preferably the resulting dispersion will be suitable for paediatric administration.

15

Some preferred compositions are detailed in the following examples, in which dissolution data is provided for Examples 4, 5 and 6. However it will be appreciated that the invention is not to be limited to these examples.

20 Example 1

Clarithromycin (83.3 g) and polycarbophil (50 g) were thoroughly blended together for 10 minutes in the mixing bowl of a planetary mixer. Ethanol (212 g) was slowly added to the powders whilst mixing over a period of 15 minutes. Mixing was continued for 10 minutes. The wet mass was dried at 50°C. The dried granule was
25 passed through a Comil fitted with a 800 µm screen. A second granulation was carried out using the previously processed granule and a 10% aqueous solution of polyvinyl pyrrolidone (PVP) K90 (45 g). The wet mass was dried at 50°C for 18 hours and then milled, sieved and the fraction 180 - 500 µm collected. The finished granule was robust and although the taste was slightly bitter a larger batch, when
30 coated, may possess the desired organoleptic qualities.

Example 2

Clarithromycin (75 g) and polycarbophil (45 g) were thoroughly blended together in the mixing bowl. Whilst stirring the blend a solution of PVP K90 (6.6 g) in ethanol (66.6 g) was added to form a wet mass. The wet mass was dried at 50°C for 15 hours and then milled and sieved. The resultant granule was robust but as before the taste was unsatisfactory.

10 Example 3

Clarithromycin (50 g) and polycarbophil (30 g) were thoroughly blended together in the mixing bowl. Granulating fluid comprising Ethanol and purified water in the ratio 50:50 was added to the mixing powders over a period of 1 hour to form a wet mass. The wet mass was milled to provide a suitable texture for drying. After drying at 50°C the granule was milled through a 800 µm screen and regranulated with a 10% w/w aqueous solution of PVP K90 (50 g). Again the wet mass was dried at 50°C until the LOD <3%. The dried granule was milled and sieved with the fraction 180 - 500 µm retained. Although the finished granule possessed a residual bitter aftertaste, the ethanol/purified water granulating fluid allowed for a smoother initial granulating process.

20 Example 4

Clarithromycin (375 g) and Polycarbophil (225 g) were thoroughly blended in the mixing bowl. The blended powders were granulated using ethanol/purified water (50:50) (800 g) over a period of 1 hour. As per previous examples the wet mass was dried and sized prior to a second granulation with 10% w/w aqueous PVP K90 solution (316 g). The fraction (180 - 710 µm) collected after milling and sieving was coated with Eudragit L 100-55 in a fluid bed apparatus using the bottom spray technique in the Wurster mode. When tested in dissolution medium at pH 6.8 the prepared granule exhibited a satisfactory dissolution profile. The taste characteristic

8

of the granule blended with other excipients and reconstituted with water was satisfactory, the bitterness of clarithromycin being masked for a 14 day storage period.

5

Assay - Bottom 249mg/g

Dissolution - Simulated Gastric Fluid

Time(min)	0	30	60	90	120	180	240
% Dissolved	0.0	0.0	0.0	0.0	0.0	0.0	0.0

10

Dissolution - Phosphate Buffer pH 6.8

Time(min)	0	15	30	45	60
% Dissolved	0.0	46.4	82.7	96.0	101.1

15

Example 5

Clarithromycin (750 g) and polycarbophil (450 g) were blended and divided into 4 equal portions. Each portion was granulated with a blend of ethanol/purified water (50:50) (350 g). The granulating fluid was added at a rate of approximately 10 ml/minute with continuous mixing. The combined wet masses were then processed as per the attached chart. The granule was split into two portions prior to fluid bed coating. One portion was coated by the bottom spray technique whilst the other portion was coated by the top spray technique. Both techniques yielded a useable granule possessing a good taste masking characteristic. In both cases a certain degree of secondary granulation was noted during the coating process which would require optimisation.

30

Assay - Bottom 247mg/g

5 Top 289mg/g

Dissolution - Phosphate Buffer pH 6.8

Time(min)	Sample	0	15	30	45	60
% Dissolved	Bottom	0.0	5.3	18.3	30.7	38.6
	Top	0.0	4.5	12.8	21.9	29.8

10

15

Example 6

20 A thoroughly mixed blend of clarithromycin (750 g) and polycarbophil (450 g) was granulated as per the attached flow chart using ethanol/water (1.3 kg) added over a period of 1 hour and subsequently 10% PVP K90 (635 g). During processing the product temperature was monitored to ensure that 60°C was not exceeded. The finished granule was tested for moisture content which averaged 3.8% (LOD). As

25 part of the coating process using the top spray technique samples were removed periodically to evaluate the ability of differing levels of coat to mask the bitter taste. It was found that taste masking was effective after 386 g of Eudragit L 100-55 polymer had been applied.

Assay - 1 341mg/g

2 290mg/g

3 250mg/g

5 4 238mg/g

Dissolution – Phosphate Buffer pH 6.8

Time(min)	Sample	0	15	30	45	60
10 % Dissolved	1	0.0	47.8	78.1	87.5	89.9
	2	0.0	46.4	84.1	93.3	94.3
	3	0.0	43.6	87.0	100.2	103.7
	4	0.0	36.6	83.6	97.7	101.5

15 Throughout the description and claims of this specification the word “comprise” and variations of that word such as “comprises” and “comprising” are not intended to exclude other additives, components, integers or steps.

CLAIMS

- 5
- 1 A composition suitable for oral administration comprising a macrolide and a polycarbophil.
- 10
2. The oral composition according to claim 1 wherein the macrolide is selected from the group comprising erythromycin A, erythromycin B, erythromycin C, erythromycin D, clarithromycin, dirithromycin, josamycin, midecamycin, kidasamycin, tylosin, roxithromycin, rokitamycin, oleandomycin, miocamycin, flurithromycin, rosarmicin, spiramycin and azithromycin.
- 15
3. The composition of claim 1 wherein the macrolide is clarithromycin.
4. The oral composition according to claim 1 or claim 2 wherein the weight ratio of macrolide to polycarbophil is between about 1:10 and about 5:1.
- 20
5. The oral composition according to claim 1 or claim 2 wherein the weight ratio of macrolide to polycarbophil is between about 1:2 and about 5:2.
6. The composition of claim 1 or claim 2 wherein the weight ratio of macrolide to polycarbophil is about 5:3
- 25
7. The composition of any one of claims 1-6 comprising an ionic complex of macrolide and polycarbophil.
- 30
8. The composition of any one of claims 1-7 in a granular form suitable for the preparation of liquid suspensions or dispersions or for formulating into chewable tablets.

9. A process for preparing granules of a macrolide and a polycarbophil comprising the steps of:

- 5 (i) mixing a macrolide and a polycarbophil in a weight ratio of macrolide to polycarbophil is between about 1:10 and about 5:1,
- (ii) wetting the mixture in a granulating solution,
- (iii) blending the wetted mixture for a time sufficient to form granules in a blender wherein the head space temperature is maintained at below 60°C, and
- 10 (iv) drying and screening the resultant dried mass to form the desired macrolide-polycarbophil granules.

- 10 The process according to claim 9 further comprising a second granulation procedure, the procedure comprising the steps of:

15

- (v) sizing the dried granules prepared at step (iv) with a suitable binder solution such as a 10% aqueous polyvinyl pyrrolidone (PVP) K90, and
- (vi) drying and, milling or sieving the dried mass to recover granules with a particle size of between 180 μ and 710 μ and optionally
- 20 (vii) coating the granules with a suitable enteric coating.

11. The process of claim 9 or claim 10 wherein the macrolide is selected from the group comprising erythromycin A, erythromycin B, erythromycin C, erythromycin D, clarithromycin, dirithromycin, josamycin, midecamycin,
- 25 kitasamycin, tylosin, roxithromycin, rokitamycin, oleandomycin, miocamycin, flurithromycin, rosarmicin and azithromycin.

12. The process of Claim 11 wherein the macrolide is clarithromycin.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ02/00091

A. CLASSIFICATION OF SUBJECT MATTERInt. Cl. ⁷: A61K 31/7048, 31/7042, 31/365, A61K 47/30, A 61P 31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Refer Electronic Database Consulted Below.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPAT: polycarbophil, fibercon, equilactin, mitrolan, polyacrylic acid and divinyl alcohol, macrolide, clarithromycin, erythromycin, dirithromycin, josamycin, midecamycin, kitasamycin, tylosin, roxithromycin, rokitamycin, oleandomycin, miocamycin, flurithromycin, rosarmicin, spiramycin, azithromycin.

CA and MEDLINE: as above

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/12217 A1 (INSITE VISION INCORPORATED) 9 June 1994, See page 52, lines 21-24, Claims	1-12
A	WO 00/57866 A2 (INSITE VISION INCORPORATED) 5 October 2000, Whole Specification.	1-12
P, A	WO 02/30395 A1 (PHARMACIA & UPJOHN COMPANY) 18 April 2002, Whole Specification.	1-12



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
18 July 2002

Date of mailing of the international search report

23 JUL 2002

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

SHUBHRA CHANDRA

Telephone No : (02) 6283 2264

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NZ02/00091

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO 9412217		AU 56841/94	CA 2150554	CN 1103316	
		EP 674528	US 5332582	ZA 9308945	
		US 5538721	US 5209926	AU 80907/91	
		CA 2085245	EP 660717	NZ 238240	
		US 5124154	ZA 9103908	WO 9119482	
		US 5252319	US 5256408		
WO 200057866		AU 200039203	EP 1165058	US 6239113	
WO 200230395		NONE			
					END OF ANNEX

BEST AVAILABLE COPY